Mar 15–18, 2020

AI meets genomics: understand and use genetics & genome editing to revolutionize medicine

Yue Cathy Chang (TutumGene)

Who is this presentation for?

Non-technical or Business audience

Level

Intermediate

Description

Genome editing has been dubbed a top technology that could create trillion-dollar markets in the next decade. Recent advancements in the application of AI to genomic editing are accelerating a path to transform medicine through secondary analysis (variant calling) and tertiary analysis (interpretation) of the data lifecycle. This field has also sparked an intense race in the world for leadership in precision medicine, with investments of more than $3B in 2017 alone. What are we doing with AI to identify genetic variants and mutations? What impact is being made to human health? What are the existing challenges? Where are investments going toward solving these challenges?

Yue Cathy Chang explores how AI is applied to different stages of genome sequencing in identifying, decoding, and interpreting the meaning of the genome, which leads to better diagnoses and the facilitation of drug selection and therapy design based on cell DNA. You’ll learn about the efforts in stem cell and somatic editing and their potential to correct mutations as well as AI’s role in enabling more accurate editing as you contemplate questions and considerations raised in using genome editing to “optimize” human health. You’ll also discover how companies can collaborate to enable win-win outcomes for all.

Prerequisite knowledge

machine learning basics

What you'll learn

The attendees will learn how AI is applied to genome sequencing and editing, the potential to correct mutations, and explore questions on using genome editing to optimize human health.
Photo of Yue Cathy Chang

Yue Cathy Chang

TutumGene

Yue Cathy Chang is a business executive recognized for sales, business development, and product marketing in high technology.

Cathy co-founded and is currently the CEO of TutumGene, a technology company that aims to accelerate disease curing by providing solutions for gene therapy and regulation of gene expression. She was most recently with Silicon Valley Data Science, a startup (acquired by Apple) that provided business transformation consulting to enterprises and other organizations using data science- and engineering-based solutions. Prior to that, Cathy was employee #1 hired by the CEO at venture-funded software startup Rocana (acquired by Splunk), where she served as Senior Director of Business Development focusing on building and growing long-term relationships, and notably increased sales leads 2x through building and managing indirect revenue channels.

Prior to Rocana, Cathy held multiple strategic roles at blue chip software enterprise companies as well as startups, including Corporate and Business Development at FeedZai and Datameer; Senior product management, product marketing and sales at Symantec and IBM; and Strategic Sourcing Improvement Consulting at Honeywell.

Cathy holds MS and BS degrees in Electrical and Computer Engineering from Carnegie Mellon University, MBA and MS degrees as a Leaders for Global Operations (LGO) duel-degree fellow from MIT, and two patents for her early work in microprocessor logic design.

Leave a Comment or Question

Help us make this conference the best it can be for you. Have questions you'd like this speaker to address? Suggestions for issues that deserve extra attention? Feedback that you'd like to share with the speaker and other attendees?

Join the conversation here (requires login)

Contact us

confreg@oreilly.com

For conference registration information and customer service

partners@oreilly.com

For more information on community discounts and trade opportunities with O’Reilly conferences

Become a sponsor

For information on exhibiting or sponsoring a conference

pr@oreilly.com

For media/analyst press inquires